Shigehiro Koganemaru
Kashiwa, 2778577, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Prognostic and predictive factors for the efficacy and safety of trastuzumab deruxtecan in HER2-positive gastric or gastroesophageal junction cancer.
Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Published: July 24, 2024
The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer.
Journal: Cancer research communications
Published: May 28, 2024
Potential Mechanisms of Interstitial Lung Disease Induced by Antibody-Drug Conjugates Based on Quantitative Analysis of Drug Distribution.
Journal: Molecular cancer therapeutics
Published: April 17, 2024
Special Issue: Evaluation of the Antitumor Mechanism of Armed Antibodies.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: October 07, 2023
Quantitative Analysis of the Concentration of Trifluridine in Tumor Hypoxic Regions Using a Novel Platform Combining Functional Endoscopy and Mass Spectrometry.
Journal: Clinical pharmacology and therapeutics
Published: April 12, 2023
p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab.
Journal: Scientific reports
Published: January 24, 2023
Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study.
Journal: Cancer research communications
Published: July 18, 2022
Quantitative analysis of drug distribution in heterogeneous tissues using dual-stacking capillary electrophoresis-mass spectrometry.
Journal: British journal of pharmacology
Published: April 07, 2022
New Armed Antibody"ADC: Antibody-Drug Conjugate"for Solid Tumor
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: June 17, 2021
Antibody-drug conjugates to treat gastric cancer.
Journal: Expert opinion on biological therapy
Published: July 28, 2020
U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer.
Journal: Molecular cancer therapeutics
Published: April 28, 2019
Last Updated: 09/26/2026